November 23, 2016 - By Adrian Mccoy · 0 Comments
Synbiotics Corp (NYSEARCA:SBIO) institutional sentiment decreased to 1.2 in Q2 2016. Its down -0.20, from 1.4 in 2016Q1. The ratio fall, as 14 hedge funds increased or started new positions, while 10 sold and trimmed stakes in Synbiotics Corp. The hedge funds in our partner’s database now own: 573,557 shares, down from 626,339 shares in 2016Q1. Also, the number of hedge funds holding Synbiotics Corp in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 5 Reduced: 5 Increased: 9 New Position: 5.
ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) has declined 0.04% since April 21, 2016 and is downtrending. It has underperformed by 5.37% the S&P500.
Virtu Financial Llc holds 0.18% of its portfolio in ALPS Medical Breakthroughs ETF for 60,502 shares. Murphy Capital Management Inc owns 9,950 shares or 0.03% of their US portfolio. Moreover, Commonwealth Equity Services Inc has 0.01% invested in the company for 77,328 shares. The Pennsylvania-based Janney Montgomery Scott Llc has invested 0.01% in the stock. Kcg Holdings Inc., a New Jersey-based fund reported 22,583 shares.#img1#
More notable recent ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) news were published by: Quotes.Wsj.com which released: “DOW JONES, A NEWS CORP COMPANY” on March 01, 2015, also Zacks.com with their article: “ALPS Puts Twist on Biotech Investing with Medical Breakthrough ETF” published on January 14, 2015, Businesswire.com published: “â€œALPS Medical Breakthroughs ETFâ€ Looks to Capitalize on New Era for Drug Companies” on December 31, 2014. More interesting news about ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) were released by: Seekingalpha.com and their article: “SBIO: A Safe Play In Biotechnology?” published on June 10, 2015 as well as Nasdaq.com‘s news article titled: “The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology ETF, SPDR S&P …” with publication date: February 02, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy